What’s New at Conigen: Bioactive Recombinant Proteins for Drug Discovery and Antibody Screening
Conigen Bioscience is expanding its portfolio of functional conformational recombinant proteins — designed to mimic native protein structure and function for drug discovery, antibody screening, and translational research.
These recombinant proteins are designed using either the CSP™ (Conigen Soluble Protein) or CMP™ (Conigen Membrane Protein) technology platforms. Each protein is validated to preserve receptor-ligand binding activity and conformational epitopes critical to immune recognition, therapeutic targeting, and lead molecule screening. Some examples include:
- Immune Checkpoint Receptors: CTLA-4, TIGIT, CD28, CD155
- Tumor Associated Antigens: TROP-2, Nectin-4
- Growth Factor Receptors: VEGFR2, FGFR1
- Cytokine Receptors: IFNgR1, IL10Ra, IFNaR1/R2
- T Cell Receptors & Co-Receptors: CD4
- Siglecs: Siglec-6
- B Cell Receptors and Surface Markers: CD19
Why It Matters:
Our approach reflects a simple principle: proteins work best when they look and act the way they do in nature. Conigen’s conformational recombinant proteins offer more reliable tool-molecules for more confident discovery:
- Native-like structures for more physiologically relevant assays
- Higher bioactivity for functional screening and antibody discovery
- Reduced need for re-screening during validation workflows
Explore Our Approach: Nature did it first. We make it available.
Conigen recombinant proteins are available as catalog items or as starting points for custom development. Every protein is developed with one goal in mind: creating native-like research tools that move your science forward with greater confidence.
Download your copy of “Recombinant Conformational Proteins: Novel bioactive soluble dimer and multi-pass membrane proteins to enhance drug discovery”